Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5TQ2O)

• Drug Name: Galangin Drug Info
• Synonyms: Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; UNII-142FWE6ECS; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; EINECS 208-960-4; NSC407229; FLAVONE, 3,5,7-TRIHYDROXY-; NSC 407229; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; BRN 0272179; 142FWE6ECS; 3,5,7-trihydroxy-2-phenylchromen-4-one; CHEBI:5262; CHEMBL309490; VCCRNZQBSJXYJD-UHFFFAOYSA-N; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5281616
  ChEBI ID: CHEMBL309490
  CAS Number: CAS 548-83-4
  TTD Drug ID: DM5TQ2O

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[10]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[11]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[12]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[13]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[14]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[15]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[16]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[17]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[13]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[13]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[18]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[19]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[20]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[21]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[22]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[23]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[11]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[24]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[25]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[26]

Drug(s) Targeting Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PINOCEMBRIN	DM96VWD	N. A.	N. A.	Phase 2	[4]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[4]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[4]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[4]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[4]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[4]
ACACETIN	DMQOB0X	Discovery agent	N.A.	Investigative	[4]
TRISMETHOXYRESVERATROL	DM6USPC	Discovery agent	N.A.	Investigative	[27]
CHRYSOERIOL	DM96ECL	Discovery agent	N.A.	Investigative	[4]
DIOSMETIN	DM4KXIM	Discovery agent	N.A.	Investigative	[4]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[29]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[30]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[31]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[33]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[34]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[35]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[36]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[38]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[39]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[40]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[41]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[42]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[43]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[44]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[45]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[46]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[44]

Drug(s) Affected By Mothers against decapentaplegic homolog 6 (SMAD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[53]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[54]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[55]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[56]

Drug(s) Affected By Ubiquitin-like protein ATG12 (ATG12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Selenium	DM25CGV	N. A.	N. A.	Approved	[58]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[59]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[60]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[61]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[62]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[63]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[64]
Artesunate	DMR27C8	Infection of P. falciparum	1F40	Approved	[65]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[66]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[67]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[68]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[69]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[70]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[72]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[74]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[75]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[76]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[77]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[78]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[79]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[80]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[81]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[82]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[81]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[83]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[84]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[85]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[86]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[87]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[88]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[89]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[70]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[91]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[92]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[82]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[93]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[94]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[95]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[80]
Selenium	DM25CGV	N. A.	N. A.	Approved	[58]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[96]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[59]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[97]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[98]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[99]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[100]

Drug(s) Affected By Mothers against decapentaplegic homolog 4 (SMAD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[103]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[104]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[106]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[108]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[64]

Drug(s) Affected By Mothers against decapentaplegic homolog 2 (SMAD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[101]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[102]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[110]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[111]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[112]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[113]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]

Drug(s) Affected By Mothers against decapentaplegic homolog 1 (SMAD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[115]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[106]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[64]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[117]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[118]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[119]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[120]

Drug(s) Affected By Autophagy-related protein 16-1 (ATG16L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[121]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[59]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[122]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[123]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[64]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[124]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[118]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[125]

Drug(s) Affected By Endothelial PAS domain-containing protein 1 (EPAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[109]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[126]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[8]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[127]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[111]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[128]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[128]

Drug(s) Affected By Ubiquitin-like-conjugating enzyme ATG3 (ATG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[129]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[130]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[131]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[61]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[37]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[132]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[107]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[131]
Artesunate	DMR27C8	Infection of P. falciparum	1F40	Approved	[65]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[2]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[3]
Cytochrome P450 1B1 (CYP1B1)	TTI84H7	CP1B1_HUMAN	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[5]
Autophagy-related protein 16-1 (ATG16L1)	OTEOYC5D	A16L1_HUMAN	Gene/Protein Processing	[6]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[7]
Endothelial PAS domain-containing protein 1 (EPAS1)	OTRE3O8U	EPAS1_HUMAN	Gene/Protein Processing	[8]
Mothers against decapentaplegic homolog 1 (SMAD1)	OTQSHR25	SMAD1_HUMAN	Gene/Protein Processing	[6]
Mothers against decapentaplegic homolog 2 (SMAD2)	OTC6VB4K	SMAD2_HUMAN	Gene/Protein Processing	[6]
Mothers against decapentaplegic homolog 4 (SMAD4)	OTWQWCKG	SMAD4_HUMAN	Gene/Protein Processing	[6]
Mothers against decapentaplegic homolog 6 (SMAD6)	OTUZZWUD	SMAD6_HUMAN	Gene/Protein Processing	[6]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Gene/Protein Processing	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 410).
• [2] Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem. 1997 Aug 1;40(16):2588-95.
• [3] Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8.
• [4] Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
• [5] 3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: Implication for inflammatory bowel disease. Pharmacol Res. 2015 Oct;100:64-72.
• [6] Galangin suppresses HepG2 cell proliferation by activating the TGF- receptor/Smad pathway. Toxicology. 2014 Dec 4;326:9-17. doi: 10.1016/j.tox.2014.09.010. Epub 2014 Sep 28.
• [7] Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo. Chem Biol Interact. 2014 Dec 5;224:149-56. doi: 10.1016/j.cbi.2014.10.027. Epub 2014 Nov 4.
• [8] Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J Cell Biochem. 2008 Apr 15;103(6):1989-98. doi: 10.1002/jcb.21588.
• [9] Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR). Toxicol Lett. 2015 Mar 4;233(2):68-77.
• [10] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [11] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [12] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [13] 2011 Pipeline of Can-Fite BioPharm.
• [14] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [15] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [16] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [17] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [18] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [21] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [22] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [24] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [25] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [26] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [27] Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.
• [28] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [29] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [30] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [31] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [32] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [33] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [34] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [35] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [36] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [37] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [38] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [39] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [40] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [41] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [42] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [43] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [44] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [45] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [46] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [47] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [48] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [49] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [50] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [51] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [52] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [53] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [54] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [55] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [56] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [57] Time course study of A formation and neurite outgrowth disruption in differentiated human neuroblastoma cells exposed to H2O2: protective role of autophagy. Toxicol In Vitro. 2013 Sep;27(6):1780-8. doi: 10.1016/j.tiv.2013.05.005. Epub 2013 May 29.
• [58] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [59] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [60] Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
• [61] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [62] Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
• [63] Mitochondrial DNA deletions and chloramphenicol treatment stimulate the autophagic transcript ATG12. Autophagy. 2007 Jul-Aug;3(4):377-80. doi: 10.4161/auto.4239. Epub 2007 Jul 5.
• [64] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [65] Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway. Biomed Pharmacother. 2019 Jan;109:2043-2053. doi: 10.1016/j.biopha.2018.11.030. Epub 2018 Nov 26.
• [66] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [67] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [68] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [69] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [70] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [71] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [72] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [73] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [74] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [75] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [76] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [77] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [78] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [79] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [80] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [81] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [82] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [83] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [84] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [85] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [86] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [87] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [88] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [89] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [90] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [91] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [92] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [93] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [94] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [95] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [96] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [97] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [98] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [99] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [100] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [101] Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma. 2004 Nov;57(5):1032-7. doi: 10.1097/01.ta.0000114087.46566.eb.
• [102] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [103] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [104] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [105] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [106] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [107] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [108] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [109] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [110] Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
• [111] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [112] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [113] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [114] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [115] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [116] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [117] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [118] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [119] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [120] The role of sirtuin 1 in osteoblastic differentiation in human periodontal ligament cells. J Periodontal Res. 2011 Dec;46(6):712-21. doi: 10.1111/j.1600-0765.2011.01394.x. Epub 2011 Jul 11.
• [121] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [122] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [123] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [124] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [125] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [126] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [127] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [128] Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res. 2003 Aug 1;9(8):3150-7.
• [129] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [130] Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
• [131] Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
• [132] Endoplasmic reticulum stress contributes to autophagy and apoptosis in cantharidin-induced nephrotoxicity. Food Chem Toxicol. 2022 May;163:112986. doi: 10.1016/j.fct.2022.112986. Epub 2022 Apr 6.